A statement released earlier today by N+1 Singer about Dechra Pharmaceuticals PLC (LON:DPH) maintains the target price at 1,350.00GBX
- Updated: September 15, 2016
In a report issued 9/16/2016 N+1 Singer maintained the target price of Dechra Pharmaceuticals PLC (LON:DPH) at 1,350GBX indicating a possible downside of -0.02%.
Previously on 9/09/2016, N+1 Singer released a statement about Dechra Pharmaceuticals PLC(LON:DPH) dropped the target price from 13,500.00GBX to 1,350.00GBX. At the time, this indicated a possible upside of 0.01%.
Just yesterday Dechra Pharmaceuticals PLC (LON:DPH) traded 1.10% higher at 1,377.50GBX. DPH’s 50-day moving average is 1,342.54GBX and its two hundred day moving average is 1,203.89GBX. The last stock close is up 14.21% relative to the 200-day average, compared with the Standard & Poor’s 500 Index which has fallen -0.01% over the same time. 168,853 shares of Dechra Pharmaceuticals PLC exchanged hands, up from ann avg. trading volume of 132,933.
With a market capitalization of 0.0 GBX, Dechra Pharmaceuticals PLC has a one-year low of 811.00GBX and a 52 week high of 1,423.00GBX with a P/E ratio of 98.
A total of 8 equity analysts have released a ratings update on the company. One firm rate the company a strong buy, five analysts rate the stock a buy, two firms rate the stock a hold, 0 rate the stock to underperform, and lastly 0 analystsrate the company as sell with a one year target of 1,263.63GBX
Brief Synopsis About Dechra Pharmaceuticals PLC (LON:DPH)
Dechra Pharmaceuticals PLC is a veterinary pharmaceuticals company. The Company is engaged in the development, manufacture and marketing of products for veterinarians across the world. The Company’s segments include European Pharmaceuticals, consists of Dechra Veterinary Products EU and Dechra Pharmaceuticals Manufacturing; North American (NA) Pharmaceuticals, consists of Dechra Veterinary Products US and Dechra Veterinary Products Canada, and Pharmaceuticals Research and Development. The European Pharmaceuticals segment manufactures and markets companion animal, equine and food producing animal products. The North American (NA) Pharmaceuticals segment sells companion animal and equine products. The Pharmaceuticals Research and Development Segment include all of the Company’s pharmaceutical research and development activities. Its products include Vetoryl, Felimazole, Isaderm, CleanAural, Sedator, Lubrithal, Equipalazone, Rapidexon, Soludox and Atipam, and among others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.